Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Cancer immunotherapy in patients with brain metastases

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Exercise and cancer: from "healthy" to "therapeutic"?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. PD-L1-specific T cells

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Broadening the repertoire of melanoma-associated T-cell epitopes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Adaptive hybrid surgery analysis (AHSA) for adjuvant gamma knife radiosurgery treatment of vestibular schwannoma residuals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Response to: neurosurgical procedures performed during residency in Europe-preliminary numbers and time trends

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Surgical treatment for symptomatic ventriculus terminalis: case series and a literature review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Zhenjiang Liu
  • Thomas Poiret
  • Oscar Persson
  • Qingda Meng
  • Lalit Rane
  • Jiri Bartek
  • Julia Karbach
  • Hans-Michael Altmannsberger
  • Christopher Illies
  • Xiaohua Luo
  • Inti Harvey-Peredo
  • Elke Jäger
  • Ernest Dodoo
  • Markus Maeurer
Vis graf over relationer

The prognosis for patients with glioblastoma is grim. Ex vivo expanded tumor-associated antigen (TAA)-reactive T-cells from patients with glioma may represent a viable source for anticancer-directed cellular therapies. Immunohistochemistry was used to test the survivin (n = 40 samples) and NY-ESO-1 (n = 38 samples) protein expression in tumor specimens. T-cells from peripheral blood were stimulated with TAAs (synthetic peptides) in IL-2 and IL-7, or using a combination of IL-2, IL-15 and IL-21. CD4+ and CD8+ T-cells were tested for antigen-specific proliferation by flow cytometry, and IFN-γ production was tested by ELISA. Twenty-eight out of 38 cancer specimens exhibited NY-ESO-1 protein expression, 2/38 showed a strong universal (4+) NY-ESO-1 staining, and 9/40 cancer lesions exhibited a strong (4+) staining for survivin. We could detect antigen-specific IFN-γ responses in 25% blood samples for NY-ESO-1 and 30% for survivin. NY-ESO-1-expanded T-cells recognized naturally processed and presented epitopes. NY-ESO-1 or survivin expression in glioma represents viable targets for anticancer-directed T-cells for the biological therapy of patients with glioma.

OriginalsprogEngelsk
TidsskriftCancer immunology, immunotherapy : CII
Vol/bind67
Udgave nummer2
Sider (fra-til)237-246
ISSN0340-7004
DOI
StatusUdgivet - 2018

ID: 52379439